通过 in situ 疫苗增强全身瘤抑制,该疫苗将辐射和 OX40 激动剂与 CpG 治疗结合起来
Zhichen Sun1,2,3, Yanhong Chu1,4, Jie Xiao1,4
1The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China.
Journal of translational medicine
|September 12, 2023
概括
一种结合辐射,TLR9激动剂CpG和OX40激动剂的新型三重现场疫苗显示出显著的抗瘤效果和改善的生存率. 这种方法与检查点阻塞疗法协同作用,显示了个性化癌症治疗的巨大潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 现场瘤疫苗是一种有前途的个性化治疗方法.
- 目前的疫苗设计需要优化以提高有效性.
- 需要对免疫机制进行更深入的研究.
研究的目的:
- 建立和评估一种新的三倍现场疫苗战略.
- 调查潜在的免疫反应和瘤微环境变异.
- 为了探索与检查点阻塞疗法的协同效应.
主要方法:
- 开发了一种结合局部辐射,TLR9激动剂 (CpG) 和OX40激动剂的三重现场疫苗.
- 在B16F10黑色素瘤模型中评估了抗瘤疗效和生存益处.
- 通过多参数流细胞计和RNA测序来分析免疫反应.
主要成果:
- 三重疫苗 (RT+CpG+αOX40) 显示增强的瘤抑制与最小的毒性.
- 它诱导了全身抗瘤反应,导致优越的瘤控制和生存.
- 该疫苗与抗编程细胞死亡蛋白 (PD) -1疗法协同作用,改善治疗结果.
结论:
- 三重局部疫苗有效诱导抗瘤反应和全身瘤控制.
- 它显示出与检查点阻塞疗法的显著协同潜力.
- 这一策略显示了作为单疗法或组合治疗的临床应用的前景.
相关概念视频
Tumor Immunotherapy
554
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
554
Cancer Vaccines
399
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
399
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


